CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease
Status:
Not yet recruiting
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
Frailty and sarcopenia are modifiable risk factors for morbidity and mortality in patients
with ESRD. Exercise is the recommended intervention to prevent frailty and sarcopenia,
however, many clinical trials have shown limited clinical improvement in muscle mass and
physical function. We propose that mitochondrial dysfunction is one of the deterrents to the
effectiveness of the exercise. We plan to evaluate the additive effect of HIIT and CoQ10, a
mitochondrial-targeted therapy, on mitochondrial function and physical performance.
Understanding the interplay among CoQ10, exercise, and mitochondrial function will identify
novel mechanisms to improve the efficiency of exercise. This will also serve to prevent
frailty, sarcopenia, and muscle dysfunction in patients with ESRD.